Evans syndrome
ICD-10 D69.3 · ICD-11 3A20.5

What Is the First-Line Treatment of Evans Syndrome?

Evans syndrome is characterised by the concurrent or sequential occurrence of immune thrombocytopenia and autoimmune haemolytic anaemia. First-line management targets both cytopenias simultaneously, with specific provisions for severe presentations and for patients who do not achieve an adequate initial response.

Treatment Approach
Corticosteroid therapy is the cornerstone of first-line management. The protocol includes a recognised alternative corticosteroid regimen and additional supportive interventions for patients with severe manifestations. Management of insufficient initial response is also addressed. The complete regimen, decision algorithm, and escalation criteria are available in the full protocol.
Response Targets
An initial response is achieved in approximately 80% of patients. The protocol defines specific thresholds for partial response (platelet count and haemoglobin criteria) and complete response (normalisation of both parameters with resolution of active haemolysis). Failure to reach partial response, or corticosteroid-dependency at a maintaining dose, triggers escalation to a second-line approach.
Instant Access to Structured Evidence-Based Regimens

References

  1. Corticosteroids remain the cornerstone of first-line treatment — predniso(lo)ne at the initial daily dose of 1 mg/kg is the standard of care.
  2. The efficacy of repeated courses of dexamethasone toward predniso(lo)ne has not been specifically tested in ES, but based on the data available in ITP, it can be viewed as a relevant alternative.
  3. In case of severe bleeding manifestations, the use of IVIg at a dose of 1 to 2 g/kg in combination with corticosteroids is required to avoid a life-threatening hemorrhage, whereas IVIg has only a little efficacy for the management of severe wAIHA.
  4. For patients with severe wAIHA, transfusion of packed RBCs must not be postponed, and the transient use of recombinant erythropoietin may be useful for those patients with severe wAIHA and an inadequate reticulocytosis.
  5. Predniso(lo)ne is usually maintained at the initial dose for 3 weeks followed by progressive weaning over at least 3 months as usually recommended for adult wAIHA.
  6. For patients not responding to predniso(lo)ne, the daily dose can be transiently increased up to a maximum of 2 mg/kg, although the efficacy of such a dose has never been fully demonstrated.
  7. In the absence of initial response (≈20% of the patients), or in case of corticosteroid-dependency with the need of maintaining a daily dose of predniso(lo)ne of more than 10 mg to maintain at least a partial response (i.e., a platelet count ≥30 × 10&sup9;/L with at least a doubling of the initial count and/or a Hb level ≥10 g/dL with at least a 2 g increase from baseline), a second-line therapy is needed.
  8. Complete response — haemoglobin level greater than 12 g/dL without ongoing haemolysis and platelet count ≥100 × 10&sup9;/L.
View source ↗